HilleVax, Inc. is a clinical-stage biopharmaceutical company dedicated to creating and marketing revolutionary vaccines. Their primary focus is on HIL-214, a vaccine made from virus-like particles, for the prevention of norovirus-induced acute gastroenteritis. The company is situated in Boston, Massachusetts.